EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Comparison of Metformin Combinations with Other Repurposed Drugs in the Treatment of Hamster Fibrosarcoma: A Review

Dušica J Popović iD, Kosta J Popović iD, Dejan Miljković iD, Mihalj Poša iD, Zana Dolićanin iD, Ivan Čapo iD, Jovan K Popović iD

Pharmaceuticals · 2026-08-09 · 19 (8) · 1254

DOI: 10.3390/ph19081254 ↗

At a glance

Übersichtsarbeit in Pharmaceuticals, published online on 2026-08-09. Written by Dušica J Popović and 6 co-authors. Institution: Department of Biomedical Sciences, State University of Novi Pazar, Vuka Karadžića 9, 36300 Novi Pazar, Serbia. 131 references. The full text is freely available (open access, CC BY 4.0). Funded by: Provincial Secretariat for High Education and Scientific Research, Autonomous Province of Vojvodina, Republic of Serbia, the Republic of Serbia, Autonomous Province of Vojvodina, Provincial Secretariat for High Education and Scientific Research.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background/Objectives: Metformin is a prominent candidate for cancer drug repurposing, backed by preclinical and epidemiological evidence showing reduced cancer incidence in diabetic patients. Its pleiotropic effects include AMPK activation, protein synthesis inhibition, and metabolic alterations. This review integrates global preclinical data via a comprehensive tabular overview alongside a cross-analysis of specific investigations of hamster fibrosarcoma. Since head-to-head comparisons of metformin-based combinations on hamster fibrosarcoma remain limited, this work performs an integrated cross-study evaluation to establish a clear comparative hierarchy of various repurposed adjuvants combined with metformin.

Methods

A literature review and cross-study re-analysis of peer-reviewed preclinical studies were conducted, focusing on in vivo therapeutic outcomes within the BHK-21/C13-induced hamster fibrosarcoma model. Treatment regimens from distinct primary studies were evaluated side-by-side using tumor endpoint data expressed as a percentage of control mean (± SD). Only statistically significant pairwise differences (p < 0.05) determined the comparative hierarchy.

Results

Integrated analysis identified disulfiram and diclofenac as the most promising adjuvants among compared metformin combinations, showing the highest statistical significance across all evaluated endpoints. The statistical ranking of the metformin-based combinations followed a descending order: disulfiram, diclofenac, nitroglycerin, itraconazole, and caffeine.

Conclusions

By synthesizing previously fragmented primary data into a unified comparative framework, these findings provide a strong, consolidated preclinical rationale for metformin-based combination strategies. The established hierarchy of adjuvant potency resolves structural ambiguity and supports further translational and clinical investigation to evaluate their therapeutic potential in fibrosarcoma and other malignancies.

Subjects

Author keywords

caffeinediclofenacdisulfiramfibrosarcomahamstersitraconazolemetforminnitroglycerin

Authors and institutions

  • Department of Biomedical Sciences, State University of Novi Pazar, Vuka Karadžića 9, 36300 Novi Pazar, Serbia.
  • Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia.
  • Department of Histology and Embryology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia.
  • Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia.
  • Academy of Medical Sciences of the Serbian Medical Society, 19 George Washington Str., 11000 Belgrade, Serbia.

ORCID profiles: Dušica J Popović, Kosta J Popović, Dejan Miljković, Mihalj Poša, Zana Dolićanin, Ivan Čapo, Jovan K Popović

Funding

  • Provincial Secretariat for High Education and Scientific Research, Autonomous Province of Vojvodina, Republic of Serbia
  • the Republic of Serbia, Autonomous Province of Vojvodina, Provincial Secretariat for High Education and Scientific Research

Cite

APA

Popović, D. J., Popović, K. J., Miljković, D., Poša, M., Dolićanin, Z., Čapo, I., & Popović, J. K. (2026). Comparison of Metformin Combinations with Other Repurposed Drugs in the Treatment of Hamster Fibrosarcoma: A Review. Pharmaceuticals, 19(8), 1254. https://doi.org/10.3390/ph19081254

Vancouver

Popović DJ, Popović KJ, Miljković D, Poša M, Dolićanin Z, Čapo I, et al. Comparison of Metformin Combinations with Other Repurposed Drugs in the Treatment of Hamster Fibrosarcoma: A Review. Pharmaceuticals. 2026;19(8):1254. doi:10.3390/ph19081254

BibTeX
@article{Popovi2026,
  author = {Popović, Dušica J and Popović, Kosta J and Miljković, Dejan and Poša, Mihalj and Dolićanin, Zana and Čapo, Ivan and Popović, Jovan K},
  title = {Comparison of Metformin Combinations with Other Repurposed Drugs in the Treatment of Hamster Fibrosarcoma: A Review},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1254},
  doi = {10.3390/ph19081254}
}
Start for free →